Table 2. Anti-ENO1 level and area under the curve in different characteristics in validation set.
| N | median | IQR | Pa | Frequency (%) | Pb | AUC | 95% CI | P | |
|---|---|---|---|---|---|---|---|---|---|
| Histology | |||||||||
| AD | 197 | 5.42 | 3.63 | 0.334 | 69 (35.0) | 0.946 | 0.579 | 0.526-0.633 | 0.003 |
| SCC | 45 | 5.91 | 2.98 | 16 (35.6) | 0.630 | 0.538-0.721 | 0.005 | ||
| Stage | |||||||||
| I and II | 33 | 6.00 | 3.58 | 0.786 | 12 (36.4) | 0.881 | 0.596 | 0.484-0.707 | 0.073 |
| III and IV | 123 | 5.55 | 3.17 | 43 (35.0) | 0.584 | 0.520-0.647 | 0.008 | ||
| Metastasis | |||||||||
| No | 122 | 5.4 | 3.76 | 0.799 | 41 (33.6) | 0.618 | 0.580 | 0.516-0.645 | 0.011 |
| Yes | 120 | 5.62 | 3.02 | 44 (36.7) | 0.598 | 0.534-0.661 | 0.002 | ||
| Smoking | |||||||||
| No | 157 | 5.71 | 4.11 | 0.486 | 57 (36.3) | 0.601 | 0.599 | 0.541-0.657 | 0.001 |
| Yes | 85 | 5.19 | 3.07 | 28 (32.9) | 0.570 | 0.497-0.643 | 0.051 | ||
| Gender | |||||||||
| Male | 144 | 5.38 | 3.3 | 0.685 | 49 (34.0) | 0.665 | 0.580 | 0.52-0.64 | 0.007 |
| Female | 98 | 5.75 | 4.38 | 36 (36.7) | 0.602 | 0.533-0.671 | 0.003 | ||
| Age | |||||||||
| ≤ 60 y | 138 | 5.78 | 3.7 | 0.390 | 50 (36.2) | 0.677 | 0.562 | 0.495-0.629 | 0.067 |
| > 60 y | 104 | 5.34 | 3.23 | 35 (33.7) | 0.626 | 0.552-0.700 | 0.001 |
AD: Adenocarcinoma; SCC: Squamous Cell Carcinoma; a: Mann-Whitney test; b: χ2 test